Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Expert Opin Drug Deliv ; 15(3): 213-222, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29257904

RESUMEN

INTRODUCTION: The oral route is widely accepted as the most physiological path for exogenous administration of insulin, as it closely mimic the endogenous insulin pathway. Thus, in this work it is proposed an innovative lipid-polymeric nanocarrier to delivery insulin orally. Areas covered: Nanoparticles were produced through a modified solvent emulsification-evaporation method, using ethyl palmitate and hydroxypropylmethylcellulose acetate succinate as matrix. Lipid-polymeric nanoparticles were around 300 nm in size, negatively charged (-20 mV) and associated insulin with efficiency higher than 80%. Differential scanning calorimetry suggested thermal stability of nanoparticles. In vitro release assays under simulated gastrointestinal conditions resulted in 9% and 14% of insulin released at pH 1.2 during 2 h and at pH 6.8 for 6 h, respectively, demonstrating the ability of those nanoparticles to protect insulin against premature degradation. Importantly, nanoparticles were observed to be safe at potential therapeutic concentrations as did not originate cytotoxicity to intestinal epithelial cells. Lastly, the permeability of nanoencapsulated insulin through Caco-2 monolayers and a triple Caco-2/HT29-MTX/Raji B cell model correlated well with slow release kinetics, and fosters the effectiveness of nanoparticles to promote intestinal absorption of peptidic drugs. Expert opinion: Lipid-polymeric nanoparticles were developed to encapsulate and carry insulin through intestine. Overall, nanoparticles provide insulin stability and intestinal permeability.


Asunto(s)
Sistemas de Liberación de Medicamentos , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Metilcelulosa/análogos & derivados , Nanopartículas/química , Ácidos Palmíticos/química , Administración Oral , Animales , Células CACO-2/efectos de los fármacos , Rastreo Diferencial de Calorimetría , Cromatografía Líquida de Alta Presión , Humanos , Concentración de Iones de Hidrógeno , Absorción Intestinal , Metilcelulosa/química , Microscopía Electrónica de Rastreo , Permeabilidad , Difracción de Rayos X
2.
Int J Pharm ; 511(1): 380-389, 2016 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-27436707

RESUMEN

The aim of this work was to develop and characterize new hyaluronic acid-based responsive materials for film coating of solid dosage forms. Crosslinking of hyaluronic acid with trisodium trimetaphosphate was performed under controlled alkaline aqueous environment. The films were produced through casting process by mixing crosslinked or bare biopolymer in aqueous dispersion of ethylcellulose, at different proportions. Films were further characterized regarding morphology by scanning electron microscopy, robustness by permeation to water vapor transmission, and ability to hydrate in simulated gastric and intestinal physiological fluids. The safety and biocompatibility of films were assessed against Caco-2 and HT29-MTX intestinal cells. The permeation to water vapor transmission was favored by increasing hyaluronic acid content in the final formulation. When in simulated gastric fluid, films exhibited lower hydration ability compared to more extensive hydration in simulated intestinal fluids. Simultaneously, in simulated intestinal fluids, films partially lost weight, revealing ability for preventing drug release at gastric pH, but tailoring the release at higher intestinal pH. The physiochemical characterization suggests thermal stability of films and physical interaction between compounds of formulation. Lastly, cytotoxicity tests demonstrated that films and individual components of the formulations, when incubated for 4h, were safe for intestinal cells Overall, these evidences suggest that hyaluronic acid-based responsive films, applied as coating material of oral solid dosage forms, can prevent the premature release of drugs in harsh stomach conditions, but control the release it in gastrointestinal tract distal portion, assuring safety to intestinal mucosa.


Asunto(s)
Química Farmacéutica/métodos , Reactivos de Enlaces Cruzados/síntesis química , Ácido Hialurónico/síntesis química , Polímeros/síntesis química , Células CACO-2 , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Reactivos de Enlaces Cruzados/farmacología , Células HT29 , Humanos , Ácido Hialurónico/farmacología , Polímeros/farmacología , Difracción de Rayos X
3.
Expert Opin Drug Deliv ; 13(9): 1301-9, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27110648

RESUMEN

INTRODUCTION: Progress in drug delivery and a better quality of life for patients, relies on the development of new and suitable drug carrier systems, with unequivocal therapeutic benefits, low systemic toxicity and reduced side effects. Lipid-polymeric nanoparticles have been explored to produce nanocarriers due to their features and applications such as high drug entrapment, physical-chemical stability and controlled release properties. AREAS COVERED: In this review, we describe several hybrid nanoparticles obtained from mixing a polymer with a lipid matrix. This association can potentiate the efficacy of drug delivery systems, due to the enhancement of encapsulation efficiency and loading capacity, tailoring the drug release according to the therapeutic purpose, and improving the drug uptake by targeting it to specific receptors. Contrary to lipid nanoparticles, these hybrid nanoparticles can decrease the initial burst release and promote a more sustained and localized release of the drug. EXPERT OPINION: Lipid-polymeric nanoparticles are versatile vehicles for drug delivery by different administration routes in the treatment of multiple diseases. Different solid lipids, polymers, surfactants and techniques for producing these carriers have been investigated, revealing the importance of their composition to achieve optimal characteristics to drug delivery.


Asunto(s)
Sistemas de Liberación de Medicamentos , Lípidos/química , Polímeros/química , Portadores de Fármacos/química , Excipientes/química , Humanos , Nanopartículas , Calidad de Vida , Tensoactivos/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA